71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results
Dan P. Zandberg, Robert L. Ferris, Douglas Laux, Ranee Mehra, Lisle M. Nabell, John M. Kaczmar, Michael K. Gibson, Y.J. Kim, P. Neupane, Julie E. Bauman, Ricklie Julian, Douglas R. Adkins, Ezra E.W. Cohen, Barbara Burtness, Candy Bermingham, A. Dupage, Antony L. Desbien, Angela Loi, D.S.A. Nuyten, Nabil F. Saba
Topics & Concepts
MedicinePembrolizumabInternal medicineAdverse effectPeripheral edemaExpanded accessInterim analysisOncologyHead and neck squamous-cell carcinomaGastroenterologyPharmacodynamicsImmunotherapyCancerClinical trialPharmacokineticsHead and neck cancerCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutationsinterferon and immune responses